Therapeutic Drug Monitoring

Breakthrough technology to enhance monoclonal antibody-based treatment

Labelled Pembrolizumab-like 13C15N

Application

Absolute quantification of Keytruda® or its biosimilars

Specific labelling

Arginine: 13C6,15N4, >99%

Lysine: 13C6,15N2, >99%

10 µg     ->    650 €      Quantity  

You must sign in or create an account to order this product

Description
Datasheet
Price

Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is used for the treatment of several types of cancer such as, Melanoma, Non-Small Cell Lung Cancer and Head and Neck Cancer. The average weight of Pembrolizumab is 146.3kDa. The pembrolizumab-like stable isotope labelled standard is suited for quantifying Pembrolizumab in human serum samples.

 

The mAb-like technology is patented.